KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2025)

Aquestive Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $1.4 million for Q4 2025, down 42.74% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (up 7.4% YoY), and the annual figure for FY2025 was $7.6 million, up 7.4%.
  • Share-based Compensation for Q4 2025 was $1.4 million at Aquestive Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Share-based Compensation for AQST hit a ceiling of $2.8 million in Q3 2025 and a floor of $344000.0 in Q1 2023.
  • Median Share-based Compensation over the past 5 years was $1.6 million (2024), compared with a mean of $1.4 million.
  • Biggest five-year swings in Share-based Compensation: tumbled 71.84% in 2022 and later skyrocketed 359.3% in 2024.
  • Aquestive Therapeutics' Share-based Compensation stood at $1.7 million in 2021, then crashed by 57.78% to $714000.0 in 2022, then skyrocketed by 31.65% to $940000.0 in 2023, then skyrocketed by 155.64% to $2.4 million in 2024, then tumbled by 42.74% to $1.4 million in 2025.
  • The last three reported values for Share-based Compensation were $1.4 million (Q4 2025), $2.8 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.